Finally, future preclinical studies and clinical trials aimed at complementing MEK inhibitors with alternative modalities, such as radiation, immunotherapy, or targeted agents against comutated genes such as CDKN2A/B, will be critical to achieve durable responses in NF1-mutant glioblastomas. This evidence concerns the gene MAP2K7 and glioblastoma.